Gordon J. Brooks

Chief Audit Executive at Eli Lilly & Company

Gordon J. Brooks

Gordon J. Brooks

Chief Audit Executive at Eli Lilly & Company

Biography

Gordon J. Brooks is on the board of ARMO BioSciences, Inc.

Overview
RelSci Relationships

1567

Number of Boards

1

Contact Data
Trying to get in touch with Gordon J. Brooks? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Gordon J. Brooks likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Vice President of Corporate Business Development at Eli Lilly & Company

Relationship likelihood: Strong

Chief Scientific Officer & Senior Vice President at Eli Lilly & Company

Relationship likelihood: Strong

President, Lilly USA at Eli Lilly & Company

Relationship likelihood: Strong

President & Chief Executive Officer at Elanco Animal House, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Eli Lilly & Company

Relationship likelihood: Strong

Former Senior Vice President & General Counsel at Eli Lilly & Company

Relationship likelihood: Strong

Senior Vice President, Information Technology & Chief Information Officer at Eli Lilly & Company

Relationship likelihood: Strong

Senior Vice President & President, Lilly Bio-Medicines at Eli Lilly & Company

Relationship likelihood: Strong

Senior Vice President, Enterprise Risk Management & Chief Ethics & Compliance Officer at Eli Lilly & Company

Relationship likelihood: Strong

Founder at ARMO BioSciences, Inc.

Relationship likelihood: Strong

Paths to Gordon J. Brooks
Potential Connections via
Relationship Science
You
Gordon J. Brooks
Chief Audit Executive at Eli Lilly & Company
Career History
Chief Audit Executive
Tenure Unconfirmed

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Boards & Committees
Director
2018 - Current

ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA.

Other Affiliations

Gordon J. Brooks is affiliated with Eli Lilly & Company, ARMO BioSciences, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gordon J. Brooks. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gordon J. Brooks's profile does not indicate a business or promotional relationship of any kind between RelSci and Gordon J. Brooks.